Pediatric growth hormone treatment in Italy: A systematic review of epidemiology, quality of life, treatment adherence, and economic impact.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Human Growth Hormone*/deficiency ; Human Growth Hormone*/economics ; Human Growth Hormone*/therapeutic use ; Prader-Willi Syndrome*/drug therapy ; Prader-Willi Syndrome*/economics ; Prader-Willi Syndrome*/epidemiology ; Quality of Life* ; Treatment Adherence and Compliance* ; Turner Syndrome*/drug therapy ; Turner Syndrome*/economics ; Turner Syndrome*/epidemiology; Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Italy/epidemiology ; Male ; Prevalence
    • Abstract:
      Objectives: This systematic review aims to describe 1) the epidemiology of the diseases indicated for treatment with growth hormone (GH) in Italy; 2) the adherence to the GH treatment in Italy and factors associated with non-adherence; 3) the economic impact of GH treatment in Italy; 4) the quality of life of patients treated with GH and their caregivers in Italy.
      Methods: Systematic literature searches were performed in PubMed, Embase and Web of Science from January 2010 to March 2021. Literature selection process, data extraction and quality assessment were performed by two independent reviewers. Study protocol has been registered in PROSPERO (CRD42021240455).
      Results: We included 25 studies in the qualitative synthesis. The estimated prevalence of growth hormone deficiency (GHD) was 1/4,000-10,000 in the general population of children; the prevalence of Short Stature HOmeoboX Containing gene deficiency (SHOX-D) was 1/1,000-2,000 in the general population of children; the birth prevalence of Turner syndrome was 1/2,500; the birth prevalence of Prader-Willi syndrome (PWS) was 1/15,000. Treatment adherence was suboptimal, with a range of non-adherent patients of 10-30%. The main reasons for suboptimal adherence were forgetfulness, being away from home, pain/discomfort caused by the injection. Economic studies reported a total cost for a complete multi-year course of GH treatment of almost 100,000 euros. A study showed that drug wastage can amount up to 15% of consumption, and that in some Italian regions there could be a considerable over- or under-prescribing. In general, patients and caregivers considered the GH treatment acceptable. There was a general satisfaction among patients with regard to social and school life and GH treatment outcomes, while there was a certain level of intolerance to GH treatment among adolescents. Studies on PWS patients and their caregivers showed a lower quality of life compared to the general population, and that social stigma persists.
      Conclusion: Growth failure conditions with approved GH treatment in Italy constitute a significant burden of disease in clinical, social, and economic terms. GH treatment is generally considered acceptable by patients and caregivers. The total cost of the GH treatment is considerable; there are margins for improving efficiency, by increasing adherence, reducing drug wastage and promoting prescriptive appropriateness.
      Competing Interests: Simona Granato, Giuseppe Novelli, Roberto Di Virgilio and Daria La Torre are employees of Pfizer. Barbara Polistena declares to have received in the last 5 years payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the following commercial sources: Allergan, Amgen, Astellas, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Janssen Cilag, Jazzpharma, Mylan, Nestlé HS, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, Shire, Takeda, Teva; in addition, she received consulting fees from UCB. Federico Spandonaro declares to have received in the last 5 years payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the following commercial sources: Allergan, Amgen, Astellas, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Janssen Cilag, Jazzpharma, Mylan, Nestlé HS, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, Shire, Takeda, Teva; in addition, he received consulting fees from Amgen. All other authors declare that they have no competing interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
    • References:
      J Public Health (Oxf). 2019 Mar 1;41(1):46-54. (PMID: 29294017)
      Pediatr Int. 2016 May;58(5):372-6. (PMID: 26617415)
      J Clin Epidemiol. 2012 Sep;65(9):934-9. (PMID: 22742910)
      Minerva Endocrinol. 2019 Sep;44(3):246-251. (PMID: 30482007)
      Clin Ther. 2008 Feb;30(2):307-16. (PMID: 18343269)
      Int J Technol Assess Health Care. 2005 Spring;21(2):240-5. (PMID: 15921065)
      Int J Equity Health. 2013 May 01;12:28. (PMID: 23634813)
      Future Sci OA. 2016 Feb 25;2(1):FSO82. (PMID: 28031934)
      J Med Genet. 2007 May;44(5):306-13. (PMID: 17182655)
      Eur J Health Econ. 2016 Apr;17 Suppl 1:99-108. (PMID: 27038627)
      N Engl J Med. 2004 Sep 16;351(12):1227-38. (PMID: 15371580)
      J Endocrinol Invest. 2016 Dec;39(12):1419-1424. (PMID: 27406716)
      J Med Genet. 2009 Dec;46(12):834-9. (PMID: 19578035)
      Acta Paediatr Suppl. 1999 Dec;88(433):109-11. (PMID: 10626558)
      Ital J Pediatr. 2018 Sep 27;44(1):113. (PMID: 30261918)
      Horm Res Paediatr. 2014;81(5):331-5. (PMID: 24714410)
      Endocr Pract. 2017 Aug;23(8):929-941. (PMID: 28614005)
      Nat Rev Nephrol. 2019 Sep;15(9):577-589. (PMID: 31197263)
      J Endocrinol Invest. 2014 Oct;37(10):979-90. (PMID: 25103591)
      J Med Genet. 2006 Sep;43(9):735-9. (PMID: 16597678)
      J Endocrinol Invest. 2010 Jun;33(6 Suppl):7-10. (PMID: 21057178)
      J Med Genet. 2003 Feb;40(2):E11. (PMID: 12566529)
      J Clin Endocrinol Metab. 2000 Jan;85(1):245-9. (PMID: 10634394)
      J Endocrinol Invest. 2017 Oct;40(10):1077-1084. (PMID: 28397185)
      J Clin Endocrinol Metab. 2002 Mar;87(3):1402-6. (PMID: 11889216)
      BMC Endocr Disord. 2011 Feb 04;11:4. (PMID: 21294891)
      Pediatrics. 2003 Apr;111(4 Pt 1):e382-7. (PMID: 12671156)
      J Endocrinol Invest. 2006 May;29(5):438-42. (PMID: 16794367)
      Am J Med Genet. 1990 Mar;35(3):319-32. (PMID: 2309779)
      J Endocrinol Invest. 2010 Jun;33(6 Suppl):15-8. (PMID: 21057180)
      Clin Endocrinol (Oxf). 2007 Jan;66(1):130-5. (PMID: 17201812)
      Eur J Endocrinol. 2020 Oct;183(4):L13-L15. (PMID: 32688337)
      Front Endocrinol (Lausanne). 2018 Mar 13;9:95. (PMID: 29593655)
      J Endocrinol Invest. 2011 May;34(5):366-9. (PMID: 21508660)
      Ital J Pediatr. 2019 Oct 21;45(1):130. (PMID: 31639023)
      J Endocrinol Invest. 2019 Oct;42(10):1241-1244. (PMID: 30968283)
      Pediatr Res. 2018 Feb;83(2):438-444. (PMID: 29211059)
      Nat Genet. 1997 May;16(1):54-63. (PMID: 9140395)
      BMJ Open. 2020 Aug 6;10(8):e036502. (PMID: 32764084)
      Ital J Pediatr. 2016 Apr 26;42:42. (PMID: 27117061)
      Front Pediatr. 2019 Jul 05;7:278. (PMID: 31334210)
      Pediatr Res. 1995 Nov;38(5):733-9. (PMID: 8552442)
      J Clin Endocrinol Metab. 2003 Oct;88(10):4891-6. (PMID: 14557470)
      Clinicoecon Outcomes Res. 2019 Aug 22;11:525-537. (PMID: 31692496)
    • Accession Number:
      12629-01-5 (Human Growth Hormone)
    • Publication Date:
      Date Created: 20220225 Date Completed: 20220308 Latest Revision: 20220308
    • Publication Date:
      20240104
    • Accession Number:
      PMC8880399
    • Accession Number:
      10.1371/journal.pone.0264403
    • Accession Number:
      35213607